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There is an unexplained strong male predominance in the aetiology of oesophageal adenocarcinoma (OAC). The hypothesis
that oestrogens are protective, deserves attention. A potential protective influence of exogenous oestrogen exposure, that is,
hormone replacement therapy (HRT) and oral contraceptives (OC) has been addressed only in studies of limited statistical
power, and the individual studies have not provided conclusive results. We conducted a systematic literature search and
meta-analysis on HRT and OC and the risk of OAC. We used the databases PubMed and the Web of Science. Odds ratios (ORs)
and 95% confidence intervals (CIs) were estimated by the Mantel–Haenszel random-effect method. A total of five studies were
included. Compared to never users, ever users of HRT had a statistically significantly decreased risk of OAC (pooled
OR50.75; 95% CI: 0.58–0.98), and ever users of OC had a borderline significantly decreased risk of this cancer (pooled
OR50.76; 95% CI: 0.57–1.00). In conclusion, HRT and OC use seems to be associated with a decreased risk of OAC. How-
ever, further research is warranted.
Oesophageal adenocarcinoma (OAC) is up to nine times
more common in men than women, yet the reasons behind
this pattern remain unclear.1,2 Gastro-oesophageal reﬂux and
high body mass index (BMI), the two main risk factors for
OAC, seem to inﬂuence the risk of developing OAC similarly
in both genders, and might not explain the male predomi-
nance.3–6 The typical male fat distribution, with mainly
abdominal adiposity, is a stronger risk factor for OAC than
BMI alone,7 but it is uncertain if this exposure contributes
the sex ratio of OAC.8 It has also been hypothesised that
female sex hormones, mainly oestrogen, are protective. This
oestrogen hypothesis is supported by a 20-year delay in the
onset of OAC in women compared to men,9 and a particu-
larly high male-to-female ratio during women’s reproductive
years.10 Individual investigations of the potential role of exog-
enous hormonal therapy in women, including hormone
replacement therapy (HRT) and oral contraceptives (OC), in
the aetiology of OAC have failed to provide conclusive
results.11–15 The low incidence of OAC in women has ham-
pered the statistical precision in the available studies. HRT is
used to mitigate discomfort caused by decreased levels of cir-
culating oestrogen and progesterone after menopause. Com-
bined HRT includes both oestrogens and progesterone, and
is recommended to women with an intact uterus, as it coun-
teracts endometrial hyperplasia associated with oestrogen
therapy. Oestrogen only HRT is recommended to women
who have undergone hysterectomy.16,17 The most commonly
used OCs contain both oestrogen and progesterone. The
often called ‘mini pill’ contains progesterone only,18 and is
recommended during breastfeeding as oestrogen reduces the
amount of breast milk.19
With the purpose of improving the knowledge of the rela-
tionship between HRT and OC exposure and risk of OAC,
we conducted a systematic review and meta-analysis.
Material and Methods
A systematic literature review and meta-analysis were per-
formed, which followed an a priori established study proto-
col. The results are reported in accordance with the PRISMA
guidelines (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses).20
Data sources and searches
The search aimed to identify all studies including data on the
associations of exogenous oestrogen, that is, HRT or use of
OC, with OAC incidence in women. No language restrictions
were applied. The time period was from an unbounded start
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date to October 25, 2013. Two scientiﬁc search engines were
used: PubMed and Web of Science. To identify relevant stud-
ies, the following terms were used: (o)esophagus, (o)esopha-
geal, cardia, or gastro-(o)esophageal junction, and neoplasms,
cancer, tumo(u)r, carcinoma, or adenocarcinoma, and
(o)estrogens, HRT, (o)estrogen replacement therapy, gonadal
hormones, gonadal steroid hormones, sex hormones, OC,
and postmenopausal hormones. Of the identiﬁed studies, ref-
erence and citation lists in the Web of Science were screened
to ﬁnd other potentially relevant articles that may have been
missed in the database search. The ﬁrst selection of the
search was performed by one investigator (K.L.) under super-
vision of the content expert (J.L.). Assessment of eligibility of
the articles remaining after exclusion of irrelevant articles
was performed by mutual consideration by all authors.
Study selection
We included studies providing original data on use of HRT or
OC in relation to the risk of developing OAC in women. Eligi-
ble studies were cohort studies, case-control studies and inter-
vention studies, providing that at least ﬁve cases of OAC were
identiﬁed. Cross-sectional studies were excluded, as were ani-
mal studies and studies only addressing nutritional oestrogens,
endogenous oestrogen exposure and oestrogen antagonists. We
also excluded studies only addressing risk of oesophageal squa-
mous cell carcinoma or studies where analyses of squamous
cell carcinoma and OAC were not reported separately.
Data synthesis and statistical analysis
Pooled risk estimates were calculated for exposure variables
reported in at least two studies. Exposure to HRT or OC
were analysed as dichotomous variables, that is, ever versus
never use. In addition, past users compared to current users,
duration and type of use of HRT or OC were analysed when-
ever possible. The data were extracted and analysed in
STATA 12.1 using the Mantel–Haenszel random-effect
method, and associations were measured in odds ratios
(ORs) or hazard ratios with 95% conﬁdence intervals (CIs).
The presence of small study effects and publication bias were
evaluated by funnel plots and EggerÇs regression asymmetry
analysis.21 Statistical heterogeneity was assessed by means of
Cochran’s Q test and I-squared test. The I-squared represents
the percentage of variation attributable to heterogeneity,
which is categorised as low (25–50%), moderate (51–75%) or
high (>75%).22
Results
Included studies
The search identiﬁed a total of 478 articles for which the
titles and abstracts were scanned to determine potential eligi-
bility for inclusion. After a selection process (summarised in
Fig. 1), ﬁve studies were ﬁnally included in the meta-analysis.
These studies together identiﬁed 451 women with OAC and
367,033 female controls.11–15 All selected studies addressed
HRT exposure,11–15 while three of these also had data on OC
exposure.11–13 These ﬁve studies were published in English
during the period 2006 and 2011. Two studies were cohort
studies11,13,14 and three were case-control studies12,14,15 (Table
1):
1. A nested case-control study based on the General Practi-
tioners Research Database in the UK included 1,619,563
person-years of follow-up and identiﬁed 58 women with
OAC and 3,191 randomly selected controls.14 The results
were adjusted for confounding by age, calendar year,
tobacco smoking, alcohol consumption, BMI, hysterectomy
and various upper gastrointestinal disorders.
2. A study pooling four population-based case-control studies,
conducted in Ireland,23 UK,24 Australia25 and US,26 and
including 218 OACs and 862 controls.12 Confounding by
age, tobacco smoking, alcohol use, education, BMI and
reﬂux were adjusted for.
3. A Chinese case-control study of 44 women with OAC and
132 hospital-based controls without any malignancy.
Adjustments were made for confounding by age, tobacco
smoking, alcohol consumption, education and reﬂux.
4. A large US cohort study including 201,506 women in the
National Institute for Healthcare-American Association of
Retired Persons NIH-AARP Diet and Health cohort,13
study with 65 cases of OAC. The study adjusted for inﬂu-
ence of age, tobacco smoking, alcohol intake, education,
BMI, physical activity and intakes of fruit, vegetables and
total energy.
5. A cohort study based on the Women’s Health Initiative
clinical trials and observational studies in the US (WHI),
including 161,080 postmenopausal women and 23 cases of
OAC.11 The WHI included both a randomised controlled
trial and an observational cohort study, both examining
effects of HRT and OC, where data were analysed com-
bined. The study adjusted the results for confounding by
age, study type, ethnicity, BMI, reﬂux and hysterectomy.
What’s new?
Because men are more often afflicted with cancer of the esophagus, estrogens may be protective for this type of cancer. In
this meta-analysis, the authors investigated whether the use of hormone replacement therapy and oral contraceptives modi-
fied the risk to develop esophageal adenocarcinoma. Hormone replacement therapy significantly decreased the risk of esopha-
geal adenocarcinoma, and the same trend was observed with oral contraceptives. These findings might prompt future
research into the potential use of hormonal therapy in selected risk groups of esophageal cancer.
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A further quality assessment of the included studies is
presented in Figure 2. All included studies had representative
populations, well-deﬁned criteria for inclusion and exclusion,
reported ever or never use of HRT and OC, and adjusted the
results for BMI. Four of the ﬁve studies also adjusted the
results for reﬂux. None of the studies exclusively assessed
risk of OAC, but all studies exclusively investigated upper
gastrointestinal cancer as the aoutcome.
Hormone replacement therapy
For the analysis of HRT use, data from all ﬁve studies were
included.11–15 Study-speciﬁc point ORs of ever HRT use ver-
sus never HRT use ranged from 0.62 to 0.96 but each of the
95% CIs included OR 5 1. The pooled OR showed a statisti-
cally signiﬁcant 25% decreased risk of OAC among ever users
of HRT compared to never users (OR 0.75, 95% CI: 0.58–
0.98). The between-study heterogeneity was low (I2 5 0%;
Fig. 3). There was limited evidence of publication bias or
small study effects bias (p 5 0.054; funnel plot not shown).
Information on the duration of HRT, expressed as less or
more than 10 years was available only in two studies.11,13
Women with less than 10 years of HRT use compared to
never users had statistically nonsigniﬁcantly reduced point
risk estimates of OAC in both studies.11,13 Among women
with more than 10 years use results were contradictory.
Among the two studies that reported data on current and
past use of HRT and analysed the two types of HRT sepa-
rately, no statistically signiﬁcant associations were found.11,13
Oral contraceptives
In the three included studies that examined the association
between use of OC and risk of OAC,11–13 the study-speciﬁc
ORs for OC users compared to non-OC users ranged from
0.70 to 0.88. The pooled OR was 24% decreased and of bor-
derline statistical signiﬁcance (OR 0.76, 95% CI: 0.57–1.00).
There was a low heterogeneity across studies (I2 5 0%; Fig.
4). There was no evidence of publication bias or small study
effects bias (p 5 0.746; funnel plot not shown).
Only one study analysed duration of OC use13 and no
meta-analysis could be conducted.
No study reported data comparing past and current use of
OC or different types of OC and the risk of OAC.
Figure 1. PRISMA flow chart of the selection of relevant studies for this meta-analysis. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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Discussion
This meta-analysis, based on ﬁve relevant studies, together includ-
ing over 300 patients with OAC from ﬁve countries, found a 25
and 24% reduced risk of OAC among women using HRT and OC.
This is, to the best of our knowledge, the ﬁrst study to
show a statistically signiﬁcantly reduced risk of OAC among
HRT users. The association between OC and OAC was less
robust in terms of the number of studies and the borderline
Figure 2. Quality assessment of the five included studies in this meta-analysis. The quality variables are listed on the Y-axis, whereas the
X-axis represents the percentages of the five studies that fulfilled the variables asked for. A 0% on the X-axis means that none of the five
studies fulfilled this criteria, whereas a 100% bar means that all studies fulfilled this criteria. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Figure 3. Forest plot-ever versus never use of Hormone Replacement Therapy. Abbreviations: HRT: Hormone Replacement Therapy, RCT:
Randomised Control Trials, OR: Odds Ratio. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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statistical signiﬁcance, but the available data indicate an asso-
ciation of similar strength to that found among HRT users.
This meta-analysis was limited by the low number of
studies, and there were insufﬁcient data to allow subgroup
analysis of duration, type or dosage of HRT and OC use or
adjust for potential confounding. The rough categorisation of
HRT or OC use into ever or never use should, however,
dilute true effects rather than enhance them, as the misclassi-
ﬁcation following such categorisation was likely to be similar
among cases and controls. As with any meta-analysis, we
cannot exclude the possibility that other studies may have
been missed during our literature search, or that studies that
observed null effects were absent from the literature alto-
gether. Nevertheless, the funnel plot and Egger’s regression
asymmetry analysis found only little evidence of presence of
small study effects and publication bias. Although the
included studies differ in several aspects, including study
design, the studies showed statistical homogeneity. The clini-
cal heterogeneity, that is, the comparability in terms of study
participants, exposure and outcome measures and other vari-
ables, is an inherent problem of meta-analyses, yet this
should be limited by virtue of the strict inclusion criteria. In
addition, potential confounding factors, that is, BMI and
reﬂux, could not be taken into account due to the limited
availability of data. However, it is unlikely that these factors
would be strongly associated with use of HRT or OC, and
thus, should not act as important confounders. Even though
the included studies had similar exclusion and inclusion cri-
teria as well as recruitment procedure, there was variability
in the exposure and patient characteristics within and
between the included studies. Due to the limited number of
studies, we could not analyse the impact of the study design
or design-speciﬁc biases, that is, recall bias and other infor-
mation biases.
There is, to the best of our knowledge, no previous meta-
analysis of exogenous oestrogen therapy and OAC. However,
some meta-analyses indicate that HRT might decrease the
risk of gastric adenocarcinoma,27,28 colorectal adenocarci-
noma28 and oesophageal cancer of any histological type.27
However, regarding oesophageal cancer it is, crucial to sepa-
rate adenocarcinoma and squamous cell carcinoma of the
oesophagus in any aetiological research, as these histological
types have very different patterns of incidence and aetiology,
including a greater level of male predominance in OAC.28
There are several mechanisms that might explain a possi-
bly preventive effect of exogenous oestrogens in OAC devel-
opment.29–31 The serum oestradiol concentration is much
higher in premenopausal women (produced mainly in the
ovaries) than in men,32 but decreases substantially after
menopause, and ultimately becomes lower than in elderly
men.33 This pattern could explain the 20-year delay in OAC
incidence among women.9 The presence of oestrogen recep-
tors has repeatedly been shown in OAC34–37 and in oesopha-
geal tissue.34,35,37,38 Involvement of oestrogen signalling in
regulation of adipose tissue metabolism indicates a possible
link between the effects of oestrogen and abdominal adiposity
(male obesity), one of the main risk factors for OAC.32,39,40
Moreover, a recent study suggests that OAC and Barrett’s
oesophagus cells respond to treatment with selective oestro-
gen receptor ligands, resulting in decreased cell growth and
apoptosis.40 Fat cells are a major source of endogenous oes-
trogen among postmenopausal women. If HRT protects
against OAC, it might be expected that the association
between body mass and OAC is weaker for women than
Figure 4. Forest plot-ever versus never use of Oral Contraceptives. Abbreviations: OC: Oral Contraceptives, OR: Odds Ratio. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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men. The adverse effects of high fat levels in women might,
to some extent, be offset by their higher oestrogen levels.
We restricted our meta-analysis to assess risk of invasive
OAC. However, given the recognised multistep progression
from gastro-oesophageal reﬂux, erosive oesophagitis, Barrett’s
oesophagus with and without dysplasia, to OAC, it would be
valuable also to investigate if oestrogens inﬂuence these ear-
lier steps in the carcinogenic pathway. Paradoxically, the risk
of gastro-oesophageal reﬂux disease has been found to be
increased among women using HRT,41–43 despite the fact
that such reﬂux is a main risk factor for OAC.5 However, it
is possible that the increased risk of reﬂux and the decreased
risk of OAC among HRT users are explained by different
timing of HRT exposure. oestrogen might, for example, pre-
vent OAC only at a later stage in the tumour progression.
There is a need for more research before any role of exog-
enous oestrogen exposure in the aetiology of OAC is estab-
lished. However, if such research shows that HRT
substantially reduces the risk of OAC, there is a potential for
future research also addressing oestrogen therapy in highly
selected risk groups of OAC, for example, patients with dys-
plastic Barrett’s oesophagus, or as adjuvant therapy in
patients with OAC, although side effects must be considered
before such research is initiated. Our study showed a reduced
risk of developing OAC of about 25% by HRT use in post-
menopausal women, and the true risk estimates might well
be lower considering the dilution of risk estimates typically
followed by rough categorisation of the exposure.44
In conclusion, this systematic review and meta-analysis
suggest that use of HRT, and possibly also OC, decreases the
risk of OAC, thus providing support for the hypothesis that
exogenous oestrogen exposure counteracts OAC in women.
These ﬁndings require more research before any association
can be established.
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